New insights into the complex role of mitochondria in Parkinson's disease

Anne Grünewald, Kishore R. Kumar, Carolyn M. Sue*

*Korrespondierende/r Autor/-in für diese Arbeit
325 Zitate (Scopus)

Abstract

New discoveries providing insights into mitochondrial bioenergetics, their dynamic interactions as well as their role in cellular homeostasis have dramatically advanced our understanding of the neurodegenerative process of Parkinson's disease (PD). Respiratory chain impairment is a key feature in sporadic PD patients and there is growing evidence that links proteins encoded by PD-associated genes to disturbances in mitochondrial function. Against the backdrop of latest advances in the development of PD treatments that target mitochondria, we aim to give an overview of the literature published in the last three decades on the significance of mitochondria in the pathogenesis of PD. We describe the contribution of mitochondrial genome alterations and PD-associated genes to mitochondrial maintenance. We highlight mitophagy as a key mechanism in neurodegeneration. Moreover, we focus on the reciprocal interaction between alpha-synuclein aggregation and mitochondrial dysfunction. We discuss a novel trafficking pathway involving mitochondrial-derived vesicles within the context of PD and provide a synopsis of the most recently emerging topics in PD research with respect to mitochondria. This includes the relationship between mitochondria and cell-mediated immunity, the ER-mitochondria axis, sirtuin-mediated mitochondrial stress response and the role of micro RNAs in the aetiology of PD. In addition, recent studies have challenged the neuro-centric view of PD pathology, moving microglia and astrocytes into the research spotlight. Greater insights into these mechanisms may hold the key for the development of novel targeted therapies, addressing the need for a disease-modifying treatment, which has remained elusive to date.

OriginalspracheEnglisch
ZeitschriftProgress in Neurobiology
Jahrgang177
Seiten (von - bis)73-93
Seitenumfang21
ISSN0301-0082
DOIs
PublikationsstatusVeröffentlicht - 06.2019

Fördermittel

Prof. Grünewald is the recipient of an ATTRACT career development grant from the National Research Fund Luxembourg (FNR). Additionally, she receives grants from the Luxembourg National Research Fund (FNR) within the INTER and CORE programmes. She is supported by the Luxemburgish Personalised Medicine Consortium (PMC) Fund and the Luxemburgish National Centre of Excellence in Research on Parkinson’s disease (NCER-PD) and the German Research Foundation (DFG). Dr. Kumar is a recipient of a National Health and Medical Research Council (NHMRC) Early Career Fellowship. Prof. Sue is a MRFF NHMRC Practitioner Fellow (APP1136800) and is supported by grants from NHMRC (1103757, 1141064, 1151906) and the NSW Genomics Collaborative Grants scheme. CMS has accepted honoraria for participating in advisory boards of Abbvie, Stada and Stealth BioTherapeutics Inc. AG is supported by grants from the Luxembourg National Research Fund (FNR) in the ATTRACT ( Model IPD, FNR9631103 ), CORE ( MiRisk-PD, FNR11676395 ) and INTER programmes ( ProtectMove, FNR11250962 ). Moreover, AG receives funding from the German Research Foundation (DFG) within the framework of the Research Unit “ProtectMove” ( GR 3731/5-1; FOR 2488/1 ), the Luxemburgish Personalised Medicine Consortium (PMC) Fund and the Luxemburgish National Centre of Excellence in Research on Parkinson’s disease (NCER-PD) . KRK is supported by NHMRC Early Career Fellowship GNT1091551 and the following grants: Kickstarter Grant, Sydney Medical School, University of Sydney ; Knowledge Discovery Project Grant (Biomedical Research), Ramsay Research and Teaching Fund ; Bushell Travelling Fellowship in Medicine or the Allied Sciences, The Royal Australasian College of Physicians Foundation ; and a Philanthropic Grant from the Paul Ainsworth Family Foundation CMS is a MRFF NHMRC Practitioner Fellow ( APP1136800 ) and is supported by grants from NHMRC ( 1103757 , 1141064 , 1151906 ), the NSW Genomics Collaborative Grants scheme, Parkinson’s NSW, Brain Foundation and the Australian Mitochondrial Disease Foundation. CMS has accepted honoraria for participating in advisory boards of Abbvie, Stada and Stealth BioTherapeutics Inc.

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „New insights into the complex role of mitochondria in Parkinson's disease“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren